Ignite Creation Date:
2024-07-17 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06477523
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-06-19
Brief Title:
Phase 1b2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
Sponsor:
Sichuan University
Organization:
Sichuan University
Study Overview
Official Title:
Phase 1b2 Study of AK104 Anti-PD1CTLA4 Bispecific Antibody in Combination With Etoposide and Carboplatin Plus Low-dose Radiotherapy LDRT for the First-line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase IbII open-label multicentre study to evaluate the efficacy and safety of low-dose radiotherapy LDRT combined with AK104 and chemotherapy as first-line treatment for patients with ES-SCLC
Detailed Description:
This trial aims to assess the safety and efficacy of a new therapeutic strategy that combines to low-dose radiotherapy combination With AK104 plus etoposide and carboplatincisplatin
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None